Dermira, Inc. (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $26.99, for a total value of $16,194.00. Following the completion of the transaction, the director now owns 32,682 shares in the company, valued at approximately $882,087.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Dermira, Inc. (NASDAQ DERM) traded down 0.51% during trading on Tuesday, hitting $27.21. 267,421 shares of the stock traded hands. The company’s market cap is $1.13 billion. The firm has a 50 day moving average price of $25.06 and a 200-day moving average price of $28.73. Dermira, Inc. has a one year low of $21.35 and a one year high of $38.75.

Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.00 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. Analysts anticipate that Dermira, Inc. will post ($4.20) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/03/david-e-cohen-sells-600-shares-of-dermira-inc-derm-stock.html.

A number of large investors have recently added to or reduced their stakes in DERM. BlackRock Inc. boosted its holdings in Dermira by 15.6% in the 2nd quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock valued at $114,294,000 after purchasing an additional 529,405 shares during the period. Jennison Associates LLC grew its position in Dermira by 16.7% in the 2nd quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock worth $76,725,000 after purchasing an additional 377,554 shares during the last quarter. TimesSquare Capital Management LLC grew its position in Dermira by 6.8% in the 1st quarter. TimesSquare Capital Management LLC now owns 2,588,661 shares of the biopharmaceutical company’s stock worth $88,299,000 after purchasing an additional 164,950 shares during the last quarter. Vanguard Group Inc. grew its position in Dermira by 9.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock worth $40,735,000 after purchasing an additional 125,157 shares during the last quarter. Finally, Voya Investment Management LLC increased its holdings in shares of Dermira by 61.4% during the 2nd quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock worth $35,783,000 after purchasing an additional 467,356 shares during the period. Hedge funds and other institutional investors own 97.56% of the company’s stock.

A number of research analysts recently commented on the company. Mizuho reissued a “buy” rating and issued a $43.00 price target (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Cantor Fitzgerald initiated coverage on Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price objective on the stock. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Evercore ISI began coverage on Dermira in a research report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 target price on the stock. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $44.40.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.